December 2016
-
AptarGroup has announced its acquisition of Nanopharm and Gateway Analytical as “part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.”… Read more . . .
-
Theravance Biopharma has named former Acorda Therapeutics Chief Business Officer Andrew Hindman as Senior VP and Chief Financial Officer. Hindman, who led Acorda’s acquisition of Inbrija inhaled L-dopa developer Civitas Therapeutics in 2014, also previously served as President… Read more . . .
-
Medical Developments International (MVP) announced that Mundipharma has acquired exclusive Australian distribution rights for the Penthrox methoxyflurane inhaler. Mundipharma already has the rights to market Penthrox in most of Europe. Mundipharma Australia and New Zealand… Read more . . .
-
Windtree Therapeutics and Eleison Pharmaceuticals have announced results from a study that demonstrated the feasibility of delivering Eleison’s inhaled lipid cisplatin (ILC) via Windtree’s Aerosol Delivery System (ADS). In March 2018, the companies announced that… Read more . . .
-
Verona Pharma has initiated a Phase 2 trial of the MDI formulation of RPL554 ensifentrine in COPD patients, the company said. Verona recently announced the initiation of a Phase 2b study of nebulized ensifentrine and… Read more . . .
-
ARS Pharmaceuticals has announced results from the EPI-04 clinical study demonstrating that the company’s ARS-1 intranasal epinephrine spray has a pharmacokinetic profile that is similar to intramuscular epinephrine. ARS is developing ARS-1 for the treatment… Read more . . .
-
The Brazilian Health Regulatory Agency (ANVISA) has approved Afrezza inhaled insulin for the treatment of diabetes, and the DPI is expected to be launched in Brazil by the end of 2019, MannKind Corporation said. MannKind announced… Read more . . .
-
Clement Clarke has announced the launch of its Clip-Tone technique guidance whistle for use with GSK’s Evohaler Ventolin and Seretide MDIs in the UK. The Clip-Tone will be available by prescription only. Like the company’s… Read more . . .
-
Novartis has announced that the Phase 3 QUARTZ study met its primary and secondary endpoints, demonstrating that low dose QMF149 indacaterol/mometasone furoate delivered via the Breezhaler DPI produced statistically significant and clinically meaningful lung function… Read more . . .
-
Nasal drug delivery specialist Kurve Technology announced that the US Department of Defense (DoD) has awarded the company a contract for testing a formulation for the treatment of traumatic brain injury (TBI). The Kurve ViaNase… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland